Get notified when PASG files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPassage Bio slashes 75% of workforce amid strategic alternatives review
Filed April 28, 2026 · Period ending April 28, 2026 · ~1 min read
Key Changes
-
high
Company cutting three-quarters of its workforce as part of strategic review to maximize shareholder value, with restructuring substantially complete by Q3 2026. This severe reduction signals major operational contraction.
Item 8.01 view on EDGAR → -
high
Strategic alternatives review ongoing, with company evaluating options including potential sale, merger, or other transactions. No certainty that any strategic alternative will be identified or completed.
Item 8.01 view on EDGAR → -
medium
Company expects approximately $3.3 million in severance and exit costs, primarily hitting Q2 2026 results. Additional costs may arise from the strategic review process.
Item 8.01 view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade PASG commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify